医薬品原薬市場 : 2029年までの世界予測

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2024年5月

Active Pharmaceutical Ingredient Market – Global Forecast to 2029

医薬品原薬市場 : タイプ（イノベーティブ医薬品、ジェネリック医薬品）、メーカー（キャプティブ、マーチャント）、合成（合成、バイオテクノロジー）、製品（mAb、ホルモン、サイトカイン）、医薬品（OTC、Rx）、用途（糖尿病、腫瘍学、CVD） – 2029年までの世界予測
Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (captive, merchant), Synthesis (Synthetic, Biotech), Products (mAb, Hormones, Cytokines), Drug (OTC, Rx), Application (Diabetes, oncology, CVD) – Global Forecast to 2029

[myphp file=”contact”]　　出版社・価格・納期について

Report Overview

The global active pharmaceutical ingredients market is projected to reach USD 238.3 billion by 2029 from USD 163.5 billion in 2024, at a CAGR of 7.8% during the forecast period of 2024 to 2029.

世界の医薬品原薬市場は、2024年から2029年の予測期間中に7.8%のCAGRで、2024年の1,635億米ドルから2029年までに2,383億米ドルに達すると予測されています。

The growth of this market can be attributed to the increasing research and development activities for the development of novel biopharmaceuticals. Biopharmaceuticals are manufactured by using living biological systems. They have become popular as they are similar to natural biological compounds found in the human body, thus offering higher efficacy and fewer side effects. Continued research in the field of biologics has resulted in the development of novel products and advancements in existing treatment models. Currently, novel concepts such as gene therapy (offering regenerative medicine) and cell therapy (for cancer treatment) are being refined. This has made biopharmaceuticals a huge and attractive opportunity area in the active pharmaceutical ingredients market. Biopharmaceuticals are currently the fastest-growing segment of the pharmaceutical industry, expected to register a double-digit growth rate in the coming decade. Their efficacy and safety, combined with their ability to address previously untreatable conditions, allow pharmaceutical companies to command high prices for these innovative drugs. Currently, a majority of blockbuster drugs are biopharmaceuticals. According to PharmaVoice report in 2023, pharmaceutical’s biggest blockbusters included Merck & Co.’s Keytruda, Pfizer and BioNTech’s COVID-19 vaccine Comirnaty, and AbbVie’s powerhouse Humira.

“The pharmaceutical & biotechnology industry segment accounted for the largest share by end user during the forecast period.”
In 2023, The pharmaceutical and biotechnology industry is a significant end user group of Active Pharmaceutical Ingredients (APIs) for drug development and manufacturing. Pharmaceutical companies utilize APIs as the primary component in their drug formulations. These compounds provide the therapeutic effects of the medication. They procure APIs to produce finished dosage forms, such as tablets, capsules, or injectables. Biotechnology firms focus on developing biologic drugs, which are derived from living organisms. These drugs typically involve complex molecules, proteins, or antibodies. Growing collaboration by pharmaceutical and biotechnology companies with API providers is one of the factors supporting market growth. For instance, in December 2022, Eli Lilly and Company and EVA Pharma collaborated through which Eli Lilly committed to supply its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Additionally, as the need for the development of novel treatments is growing, the pharmaceutical and biotechnology industry is focused on continuously innovating in this field. This is further expected to support market growth.

“Europe: The second largest region in the active pharmaceutical ingredients market.”
Europe accounted for the second-largest market for active pharmaceutical ingredients market after North America. The European active pharmaceutical ingredients market has witnessed significant growth in recent years, driven by demographic changes, such as the growing incidence of chronic diseases. This is attributed to the rising geriatric population in the region. As per the European Commission, by 2025, more than 20% of Europeans are expected to be 65 years and above, with a rapid increase in the number of people aged 80 years and above, indicating strong demand growth for healthcare facilities and disease diagnostics services. This will drive pharmaceutical and biopharmaceutical clinical trial activity for novel drug discoveries and directly contribute to the growth of associated markets, such as active pharmaceutical ingredients.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, CXOs and Directors-level – 30%, and Executives – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America- 10%, and Middle East and Africa- 5%

List of Companies Profiled in the Report:
• Pfizer Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• GSK PLC (UK)
• Sanofi (France)
• Viatris Inc. (US)
• Divi’s Laboratories Limited (India)
• Sandoz Group AG (Switzerland)
• Boehringer Ingelheim International GmBH (US)
• SK Inc. (US)
• Eli Lilly and Company (US)
• Merck KGaA (US)
• AbbVie Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AstraZeneca (UK)
• Dr. Reddy’s Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Cipla (India)
• Aurobindo Pharma (India)
• Evonik Industries AG (Germany)
• Hikma Pharmaceuticals PLC (UK)
• BASF SE (Germany)
• Alembic Pharmaceuticals Limited (India)
• Aburaihan Pharmaceutical Company (Iran)
• Curia Global, Inc. (US)
• Cambrex Corporation (US)
• API Pharma Tech (US)
• Sreepathi Pharmaceuticals Limited (India)
• Shilpa Medicare Limited (India)
• Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
• Hovione (Portugal)
• ChemCon GmbH (Germany)
• Pharco (Egypt)

Research Coverage:
This report provides a detailed picture of the active pharmaceutical ingredients market. It aims at estimating the size and future growth potential of the market across different segments such as the type, synthesis, type of drug, potency, therapeutic applications, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies. Market evaluation framework, market share analysis, revenue analysis, company evaluation matrix for the top 32 companies, SME/start-up evaluation matrix, company footprint, competitive benchmarking of SMEs/start-ups, competitive scenario, and valuation & financial metrics of key vendors have been updated in the competitive landscape chapter of the report.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges

The report provides insights on the following pointers:
• Analysis of key drivers (Production capacity expansion in pharmaceutical and biopharmaceutical companies, Growing adoption of generic drugs, Increasing uptake of biopharmaceuticals and Technological advancements in API manufacturing), restraints (Complications during API manufacturing, Low profit margins and high manufacturing costs), opportunities (Increased use of highly potent active pharmaceutical ingredients, and Potential growth opportunities in emerging economies), and challenges (Rising penetration of counterfeit drugs and Stringent regulatory requirements for API manufacturing).
• Product Development/Innovation: Detailed insights on newly launched product and technological assessment of the active pharmaceutical ingredients market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market
• Competitive Assessment: In-depth assessment of market shares, technology analysis, investment and funding scenario, company footprint analysis, growth strategies and product offerings of leading players like Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), GSK PLC (UK), Sanofi (France), Viatris Inc. (US), Divi’s Laboratories Limited (India), Sandoz Group AG (Switzerland), Boehringer Ingelheim International GmBH (US), SK Inc. (US), Eli Lilly and Company (US), Merck KGaA (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals PLC (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Aburaihan Pharmaceutical Company (Iran), Curia Global, Inc. (US), Cambrex Corporation (US), API Pharma Tech (US), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), Hovione (Portugal), ChemCon GmbH (Germany), and Pharco (Egypt).

Table of Contents

1            INTRODUCTION            74

1.1         STUDY OBJECTIVES      74

1.2         MARKET DEFINITION   74

1.3         INCLUSIONS AND EXCLUSIONS 75

1.4         STUDY SCOPE  76

1.4.1      MARKET SEGMENTATION         76

FIGURE 1           ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SEGMENTS COVERED   76

1.4.2      REGIONAL SEGMENTATION     77

FIGURE 2           ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONS COVERED          77

1.4.3      YEARS CONSIDERED     77

1.4.4      CURRENCY CONSIDERED          78

1.5         STAKEHOLDERS            78

1.6         RESEARCH LIMITATIONS           78

1.7         SUMMARY OF CHANGES            79

1.7.1      RECESSION IMPACT      79

2            RESEARCH METHODOLOGY     80

2.1         RESEARCH DATA           80

FIGURE 3           RESEARCH DESIGN       80

2.1.1      SECONDARY DATA       81

2.1.2      PRIMARY DATA 81

2.1.2.1   Breakdown of primaries     82

FIGURE 4           BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS     82

2.2         MARKET SIZE ESTIMATION       83

FIGURE 5           ACTIVE PHARMACEUTICAL INGREDIENT MARKET SIZE ESTIMATION  (SUPPLY-SIDE ANALYSIS), 2023  83

2.2.1      GLOBAL MARKET ESTIMATION 83

FIGURE 6           MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023             84

FIGURE 7           ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS (2023)            84

2.2.2      INSIGHTS FROM PRIMARY EXPERTS      86

FIGURE 8           MARKET SIZE VALIDATION FROM PRIMARY SOURCES  86

2.2.3      SEGMENTAL MARKET SIZE ESTIMATION           86

FIGURE 9           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       86

2.3         MARKET GROWTH RATE PROJECTION 87

FIGURE 10         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: CAGR PROJECTIONS  88

2.3.1      IMPACT ANALYSIS OF DEMAND-SIDE AND SUPPLY-SIDE FACTORS              88

TABLE 1             IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS           88

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    89

FIGURE 11         DATA TRIANGULATION METHODOLOGY         90

2.5         STUDY ASSUMPTIONS  90

2.6         RISK ANALYSIS 91

2.7         IMPACT OF ECONOMIC RECESSION ON ACTIVE PHARMACEUTICAL INGREDIENT MARKET  91

3            EXECUTIVE SUMMARY 93

FIGURE 12         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2024 VS. 2029 (USD BILLION)      93

FIGURE 13         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2024 VS. 2029 (USD BILLION)         94

FIGURE 14         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2024 VS. 2029 (USD BILLION)            94

FIGURE 15         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2024 VS. 2029 (USD BILLION)           95

FIGURE 16         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2023        95

FIGURE 17         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2024 VS. 2029 (USD BILLION)      96

FIGURE 18         GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENT MARKET  97

4            PREMIUM INSIGHTS      98

4.1         ACTIVE PHARMACEUTICAL INGREDIENT MARKET OVERVIEW 98

FIGURE 19         INCREASING R&D FUNDING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET          98

4.2         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE AND COUNTRY, 2023   99

FIGURE 20         US AND INNOVATIVE APIS COMMANDED LARGEST MARKET SHARE IN 2023  99

4.3         ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY SYNTHESIS, 2024 VS. 2029     99

FIGURE 21         SYNTHETIC APIS TO DOMINATE MARKET DURING FORECAST PERIOD              99

4.4         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2023              100

FIGURE 22         TRADITIONAL APIS POSSESSED LARGEST MARKET SHARE IN 2023      100

4.5         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES       100

FIGURE 23         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 100

5            MARKET OVERVIEW     101

5.1         INTRODUCTION            101

5.2         MARKET DYNAMICS     101

FIGURE 24         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       101

TABLE 2             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: IMPACT ANALYSIS          102

5.2.1      DRIVERS            102

5.2.1.1   Production capacity expansion in pharmaceutical & biopharmaceutical companies              102

5.2.1.2   Growing adoption of generic drugs  103

FIGURE 25         TOTAL SAVINGS FROM GENERIC DRUG USAGE IN US,  2013–2022 (USD BILLION)      103

TABLE 3             INDICATIVE LIST OF DRUGS GOING OFF-PATENT IN 2024              104

5.2.1.3   Increasing uptake of biopharmaceuticals        105

FIGURE 26         GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 (USD BILLION)           105

5.2.1.4   Technological advancements in API manufacturing     105

5.2.2      RESTRAINTS     107

5.2.2.1   Complications during API manufacturing      107

5.2.2.2   Low profit margin and high manufacturing cost           107

5.2.3      OPPORTUNITIES           107

5.2.3.1   Increased use of highly potent APIs 107

5.2.3.2   Potential growth opportunities in emerging economies 108

5.2.4      CHALLENGES   108

5.2.4.1   Rising penetration of counterfeit drugs          108

5.2.4.2   Stringent regulatory requirements for API manufacturing          109

5.2.5      TRENDS             109

5.2.5.1   Increased outsourcing to contract manufacturing organizations 109

5.2.5.2   Shift towards continuous processing 109

5.3         TECHNOLOGY ANALYSIS           110

5.3.1      KEY TECHNOLOGIES    110

5.3.1.1   Continuous manufacturing 110

5.3.1.2   Advanced analytical technique         110

5.3.1.3   Biocatalysis          110

5.3.2      COMPLIMENTARY TECHNOLOGIES      111

5.3.2.1   Data analytics and digitalization      111

5.3.2.2   Personalized medicine and custom synthesis  111

5.3.2.3   Supercritical fluid technology          111

5.3.3      ADJACENT TECHNOLOGIES      112

5.3.3.1   Supply chain visibility and blockchain            112

5.3.3.2   3D printing          112

5.3.3.3   Nanotechnology  112

5.4         SUPPLY CHAIN ANALYSIS          113

FIGURE 27         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SUPPLY CHAIN ANALYSIS           113

5.5         VALUE CHAIN ANALYSIS            114

FIGURE 28         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: VALUE CHAIN ANALYSIS           115

5.6         PRICING ANALYSIS        116

5.6.1      AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER 116

TABLE 4             AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER 116

5.7         ECOSYSTEM ANALYSIS 117

FIGURE 29         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ECOSYSTEM ANALYSIS 117

5.7.1      RAW MATERIAL SUPPLIERS       117

TABLE 5             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF RAW MATERIAL SUPPLIERS IN ECOSYSTEM       118

5.7.2      INGREDIENT VENDORS             118

TABLE 6             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF INGREDIENT VENDORS IN ECOSYSTEM             118

5.7.3      END USERS       119

TABLE 7             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF END USERS IN ECOSYSTEM       119

5.7.4      REGULATORY BODIES  119

TABLE 8             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF REGULATORY BODIES IN ECOSYSTEM 119

5.8         PATENT ANALYSIS        120

5.8.1      METHODOLOGY           120

5.8.2      NUMBER OF PATENTS FILED    120

TABLE 9             ACTIVE PHARMACEUTICAL INGREDIENT MARKET: NUMBER OF PATENTS FILED,  2014–2023             120

5.8.3      INNOVATION AND PATENT APPLICATIONS      120

FIGURE 30         TOTAL NUMBER OF PATENTS GRANTED FOR ACTIVE PHARMACEUTICAL INGREDIENTS, 2014–2023    120

5.8.4      TOP APPLICANTS          121

FIGURE 31         TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,  2014–2023       121

TABLE 10           TOP 20 PATENT OWNERS IN ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  2014–2023        121

5.9         KEY CONFERENCES AND EVENTS, 2024–2025     122

TABLE 11           ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025              122

5.10       REGULATORY LANDSCAPE       123

5.10.1    REGULATORY SCENARIO           123

5.10.1.1 North America     123

5.10.1.1.1            US         123

5.10.1.1.2            Canada  123

5.10.1.2 Europe  124

5.10.1.2.1            Germany             124

5.10.1.2.2            UK         124

5.10.1.3 Asia Pacific          124

5.10.1.3.1            Japan     124

5.10.1.4 Latin America      125

5.10.1.4.1            Brazil     125

5.10.1.5 Middle East & Africa          125

5.10.1.5.1            Saudi Arabia        125

5.10.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          125

TABLE 12           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         125

TABLE 13           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126

TABLE 14           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         126

TABLE 15           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         127

TABLE 16           MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         127

5.11       PORTER’S FIVE FORCES ANALYSIS         128

TABLE 17           ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PORTER’S FIVE FORCES ANALYSIS 128

5.11.1    THREAT OF NEW ENTRANTS    128

5.11.2    THREAT OF SUBSTITUTES         128

5.11.3    BARGAINING POWER OF SUPPLIERS     128

5.11.4    BARGAINING POWER OF BUYERS           128

5.11.5    INTENSITY OF COMPETITIVE RIVALRY 129

5.12       KEY STAKEHOLDERS AND BUYING CRITERIA    129

5.12.1    KEY STAKEHOLDERS IN BUYING PROCESS         129

FIGURE 32         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS        129

5.12.2    KEY BUYING CRITERIA 130

FIGURE 33         KEY BUYING CRITERIA FOR END USERS              130

TABLE 18           KEY BUYING CRITERIA, BY END USER    130

5.13       INVESTMENT AND FUNDING SCENARIO            131

5.14       TRADE DATA    132

5.14.1    IMPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)        132

TABLE 19           IMPORTERS FOR ANTIBIOTICS (HS CODE–2941)             132

5.14.2    EXPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)        137

TABLE 20           EXPORTERS FOR ANTIBIOTICS (HS CODE–2941)             137

5.14.3    IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)    140

TABLE 21           IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE–2934) 140

5.14.4    EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)    145

TABLE 22           EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE–2934) 145

5.14.5    IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)           148

TABLE 23           IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE–2937)    148

5.14.6    EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)           152

TABLE 24           EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE–2937)    152

6            ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE     156

6.1         INTRODUCTION            157

TABLE 25           ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2029 (USD BILLION)           157

6.2         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT)         157

TABLE 26           ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION) 157

TABLE 27           CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     158

6.3         INNOVATIVE APIS         158

6.3.1      INCREASING NUMBER OF  REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO BOOST MARKET GROWTH      158

TABLE 28           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY REGION,  2022–2029 (USD BILLION)        159

TABLE 29           NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022–2029 (USD BILLION)              159

TABLE 30           EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS,  BY COUNTRY, 2022–2029 (USD BILLION)          160

TABLE 31           ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS,  BY COUNTRY, 2022–2029 (USD BILLION)              160

TABLE 32           LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022–2029 (USD BILLION)              161

TABLE 33           MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS,  BY COUNTRY, 2022–2029 (USD BILLION)              161

TABLE 34           GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022–2029 (USD BILLION)              161

6.4         GENERIC APIS  162

6.4.1      INCREASED FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET GROWTH      162

TABLE 35           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY REGION,  2022–2029 (USD BILLION) 162

TABLE 36           NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022–2029 (USD BILLION)   163

TABLE 37           EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION)   163

TABLE 38           ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 164

TABLE 39           LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 164

TABLE 40           MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 165

TABLE 41           GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 165

7            ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY SYNTHESIS              166

7.1         INTRODUCTION            167

TABLE 42           ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 (USD BILLION) 167

7.2         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (CAPTIVE AND MERCHANT)     167

TABLE 43           ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS  (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)     167

TABLE 44           CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 (USD BILLION)         168

7.3         SYNTHETIC APIS            168

TABLE 45           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY REGION, 2022–2029 (USD BILLION)             169

TABLE 46           NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022–2029 (USD BILLION)              169

TABLE 47           EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION)            169

TABLE 48           ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION)              170

TABLE 49           LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022–2029 (USD BILLION)              170

TABLE 50           MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY COUNTRY, 2022–2029 (USD BILLION)              170

TABLE 51           GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022–2029 (USD BILLION)              171

7.3.1      SYNTHETIC APIS MARKET, BY TYPE      171

TABLE 52           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE,  2022–2029 (USD BILLION) 171

7.3.1.1   Innovative synthetic APIs  171

7.3.1.1.1 Innovative synthetic APIs to command larger market share during forecast period              171

TABLE 53           INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2022–2029 (USD BILLION) 172

TABLE 54           NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  172

TABLE 55           EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  173

TABLE 56           ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  173

TABLE 57           LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  174

TABLE 58           MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  174

TABLE 59           GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  174

7.3.1.2   Generic synthetic APIs      175

7.3.1.2.1 Cost effectiveness and increased government support to fuel market growth              175

TABLE 60           GENERIC SYNTHETIC APIS MARKET, BY REGION, 2022–2029 (USD BILLION) 175

TABLE 61           NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  175

TABLE 62           EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           176

TABLE 63           ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  176

TABLE 64           LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  177

TABLE 65           MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  177

TABLE 66           GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  177

7.4         BIOTECH APIS  178

TABLE 67           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY REGION,  2022–2029 (USD BILLION) 179

TABLE 68           NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022–2029 (USD BILLION)  179

TABLE 69           EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY COUNTRY, 2022–2029 (USD BILLION)  180

TABLE 70           ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 180

TABLE 71           LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 181

TABLE 72           MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY COUNTRY, 2022–2029 (USD BILLION) 181

TABLE 73           GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022–2029 (USD BILLION)  181

7.4.1      BIOTECH APIS MARKET, BY TYPE          182

TABLE 74           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE,  2022–2029 (USD BILLION)      182

7.4.1.1   Innovative biotech APIs     182

7.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive segment      182

TABLE 75           INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2022–2029 (USD BILLION) 183

TABLE 76           NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  183

TABLE 77           EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           183

TABLE 78           ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  184

TABLE 79           LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  184

TABLE 80           MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  184

TABLE 81           GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  185

7.4.1.2   Generic biotech APIs         185

7.4.1.2.1 High demand for biosimilars to propel segment growth              185

TABLE 82           GENERIC BIOTECH APIS MARKET, BY REGION, 2022–2029 (USD BILLION)           186

TABLE 83           NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  186

TABLE 84           EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           187

TABLE 85           ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)           187

TABLE 86           LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  188

TABLE 87           MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  188

TABLE 88           GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  188

7.4.2      BIOTECH APIS MARKET, BY PRODUCT 189

TABLE 89           ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT  2022–2029 (USD BILLION)            189

7.4.2.1   Monoclonal antibodies      189

7.4.2.1.1 Growing applications of antibody-drug conjugates in cancer treatment to drive segment 189

TABLE 90           MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD BILLION) 190

TABLE 91           NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  190

TABLE 92           EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           190

TABLE 93           ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  191

TABLE 94           LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  191

TABLE 95           MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  192

TABLE 96           GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  192

7.4.2.2   Hormones & growth factors             192

7.4.2.2.1 Rising incidence of hormonal imbalance among geriatric and neonatal population to aid segment growth        192

TABLE 97           HORMONES & GROWTH FACTORS MARKET, BY REGION, 2022–2029 (USD BILLION)      193

TABLE 98           NORTH AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          193

TABLE 99           EUROPE: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  194

TABLE 100         ASIA PACIFIC: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  194

TABLE 101         LATIN AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          195

TABLE 102         MIDDLE EAST: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  195

TABLE 103         GCC COUNTRIES: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          195

7.4.2.3   Fusion proteins    196

7.4.2.3.1 Growing applications in biopharmaceuticals to augment segment growth 196

TABLE 104         FUSION PROTEINS MARKET, BY REGION, 2022–2029 (USD BILLION)           196

TABLE 105         NORTH AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           196

TABLE 106         EUROPE: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 197

TABLE 107         ASIA PACIFIC: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           197

TABLE 108         LATIN AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           198

TABLE 109         MIDDLE EAST: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           198

TABLE 110         GCC COUNTRIES: FUSION PROTEINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           198

7.4.2.4   Cytokines            199

7.4.2.4.1 Effective use in regulating immune system, inflammation, and cell growth to augment segment growth   199

TABLE 111         CYTOKINES MARKET, BY REGION, 2022–2029 (USD BILLION)              199

TABLE 112         NORTH AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)      199

TABLE 113         EUROPE: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           200

TABLE 114         ASIA PACIFIC: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 200

TABLE 115         LATIN AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)      201

TABLE 116         MIDDLE EAST: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 201

TABLE 117         GCC COUNTRIES: CYTOKINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)      201

7.4.2.5   Therapeutic enzymes         202

7.4.2.5.1 Growing use in cancer and pain management therapies to drive segment 202

TABLE 118         THERAPEUTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD BILLION)           202

TABLE 119         NORTH AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  202

7.4.3      203

TABLE 120         EUROPE: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           203

TABLE 121         ASIA PACIFIC: THERAPEUTIC ENZYMES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  203

TABLE 122         LATIN AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  204

TABLE 123         MIDDLE EAST: THERAPEUTIC ENZYMES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  204

TABLE 124         GCC COUNTRIES: THERAPEUTIC ENZYMES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  204

7.4.3.1   Blood factors & anti-coagulants       205

7.4.3.1.1 Rising incidence of hemophilia to drive market            205

TABLE 125         BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY REGION, 2022–2029 (USD BILLION)           205

TABLE 126         NORTH AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       205

TABLE 127         EUROPE: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  206

TABLE 128         ASIA PACIFIC: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       206

TABLE 129         LATIN AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       207

TABLE 130         MIDDLE EAST: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       207

TABLE 131         GCC COUNTRIES: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       207

7.4.3.2   Recombinant vaccines        208

7.4.3.2.1 Increasing funding for vaccine development to boost segment growth      208

TABLE 132         RECOMBINANT VACCINES MARKET, BY REGION, 2022–2029 (USD BILLION) 208

TABLE 133         NORTH AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  208

TABLE 134         EUROPE: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)           209

TABLE 135         ASIA PACIFIC: RECOMBINANT VACCINES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  209

TABLE 136         LATIN AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  210

TABLE 137         MIDDLE EAST: RECOMBINANT VACCINES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  210

TABLE 138         GCC COUNTRIES: RECOMBINANT VACCINES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  210

7.4.4      BIOTECH APIS MARKET, BY EXPRESSION SYSTEM          211

TABLE 139         PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)            211

7.4.4.1   Mammalian expression systems       211

7.4.4.1.1 High expression level and easy scalability to propel segment growth         211

TABLE 140         MAMMALIAN EXPRESSION SYSTEMS MARKET, BY REGION, 2022–2029 (USD BILLION)           212

TABLE 141         NORTH AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       212

TABLE 142         EUROPE: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  213

TABLE 143         ASIA PACIFIC: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          213

TABLE 144         LATIN AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       214

TABLE 145         MIDDLE EAST: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          214

TABLE 146         GCC COUNTRIES: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       214

7.4.4.2   Microbial expression systems           215

7.4.4.2.1 High expression levels of proteins at low costs to augment segment growth              215

TABLE 147         MICROBIAL EXPRESSION SYSTEMS MARKET, BY REGION, 2022–2029 (USD BILLION)      215

TABLE 148        NORTH AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)             216

TABLE 149         EUROPE: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  216

TABLE 150         ASIA PACIFIC: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  217

TABLE 151         LATIN AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          217

TABLE 152         MIDDLE EAST: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  218

TABLE 153         GCC COUNTRIES: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          218

7.4.4.3   Yeast expression systems    218

7.4.4.3.1 Availability of efficient protein secretion and simple purification process to boost demand 218

TABLE 154         YEAST EXPRESSION SYSTEMS MARKET, BY REGION, 2022–2029 (USD BILLION) 219

TABLE 155         NORTH AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  219

TABLE 156        EUROPE: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)           220

TABLE 157         ASIA PACIFIC: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  220

TABLE 158         LATIN AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  221

TABLE 159         MIDDLE EAST: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  221

TABLE 160         GCC COUNTRIES: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  221

7.4.4.4   Insect expression systems   222

7.4.4.4.1 Effective post-translational modifications to boost segment growth          222

TABLE 161         INSECT EXPRESSION SYSTEMS MARKET, BY REGION, 2022–2029 (USD BILLION) 223

TABLE 162         NORTH AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  223

TABLE 163         EUROPE: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  224

TABLE 164         ASIA PACIFIC: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  224

TABLE 165         LATIN AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  225

TABLE 166         MIDDLE EAST: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  225

TABLE 167         GCC COUNTRIES: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  225

7.4.4.5   Other expression systems   226

TABLE 168         OTHER EXPRESSION SYSTEMS MARKET, BY REGION, 2022–2029 (USD BILLION) 226

TABLE 169         NORTH AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  226

TABLE 170         EUROPE: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  227

TABLE 171         ASIA PACIFIC: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  227

TABLE 172         LATIN AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  228

TABLE 173         MIDDLE EAST: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  228

TABLE 174         GCC COUNTRIES: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)  228

8            ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY TYPE OF DRUG   229

8.1         INTRODUCTION            230

TABLE 175         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)   230

8.2         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)     230

TABLE 176         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)           230

TABLE 177         CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 231

8.3         PRESCRIPTION DRUGS 231

8.3.1      INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT MARKET GROWTH          231

TABLE 178         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS,  BY REGION, 2022–2029 (USD BILLION) 232

TABLE 179         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              232

TABLE 180         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)    233

TABLE 181         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              233

TABLE 182         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              234

TABLE 183         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              234

TABLE 184         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              234

8.4         OVER-THE-COUNTER DRUGS   235

8.4.1      RISING PROMOTION OF SELF-MEDICATION TO PROPEL MARKET GROWTH          235

TABLE 185         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS,  BY REGION, 2022–2029 (USD BILLION)             235

TABLE 186         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)           236

TABLE 187         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)              236

TABLE 188         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)           237

TABLE 189         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)           237

TABLE 190         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)           237

TABLE 191         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)           238

9            ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY              239

9.1         INTRODUCTION            240

TABLE 192         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   240

9.2         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (CAPTIVE AND MERCHANT)     240

TABLE 193         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY  (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)       240

TABLE 194         CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           241

9.3         TRADITIONAL APIS       241

9.3.1      INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH    241

TABLE 195         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY REGION,  2022–2029 (USD BILLION)      242

TABLE 196         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022–2029 (USD BILLION)              242

TABLE 197         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS,  BY COUNTRY, 2022–2029 (USD BILLION)       243

TABLE 198         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022–2029 (USD BILLION)              243

TABLE 199         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022–2029 (USD BILLION)              244

TABLE 200         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022–2029 (USD BILLION)              244

TABLE 201         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022–2029 (USD BILLION)              244

9.4         HIGHLY POTENT APIS  245

9.4.1      RISING PREVALENCE OF CANCER AND GROWING APPLICATIONS IN ONCOLOGY TO AID MARKET GROWTH             245

TABLE 202         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY REGION, 2022–2029 (USD BILLION)   245

TABLE 203         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022–2029 (USD BILLION)              246

TABLE 204         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS,  BY COUNTRY, 2022–2029 (USD BILLION)  246

TABLE 205         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022–2029 (USD BILLION)              247

TABLE 206         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022–2029 (USD BILLION)              247

TABLE 207         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022–2029 (USD BILLION)              248

TABLE 208         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022–2029 (USD BILLION)              248

10          ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION   249

10.1       INTRODUCTION            250

TABLE 209         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION,  2022–2029 (USD BILLION)          250

10.2       ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)       250

TABLE 210         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)           251

TABLE 211         CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       251

10.3       COMMUNICABLE DISEASES      252

10.3.1    COMMUNICABLE DISEASES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD           252

TABLE 212         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES,  BY REGION, 2022–2029 (USD BILLION)     252

TABLE 213         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           253

TABLE 214         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              253

TABLE 215         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           254

TABLE 216         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           254

TABLE 217         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           255

TABLE 218         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           255

10.4       ONCOLOGY      255

10.4.1    INCREASING INCIDENCE OF CANCER AND RISING NUMBER OF FDA APPROVALS FOR ONCOLOGY DRUGS TO DRIVE MARKET          255

TABLE 219         LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER             256

TABLE 220         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY REGION,  2022–2029 (USD BILLION)     256

TABLE 221         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)    257

TABLE 222         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)      257

TABLE 223         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)    258

TABLE 224         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)    258

TABLE 225         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)    259

TABLE 226         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY,  BY COUNTRY, 2022–2029 (USD BILLION)    259

10.5       DIABETES         259

10.5.1    LARGE GERIATRIC POPULATION AND HIGH OBESITY RATES TO SUPPORT MARKET GROWTH    259

TABLE 227         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY REGION,  2022–2029 (USD BILLION)        260

TABLE 228         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES,  BY COUNTRY, 2022–2029 (USD BILLION)        260

TABLE 229         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022–2029 (USD BILLION)             261

TABLE 230         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES,  BY COUNTRY, 2022–2029 (USD BILLION)        261

TABLE 231         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES,  BY COUNTRY, 2022–2029 (USD BILLION)        262

TABLE 232         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES,  BY COUNTRY, 2022–2029 (USD BILLION)        262

TABLE 233         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES,  BY COUNTRY, 2022–2029 (USD BILLION)        262

10.6       CARDIOVASCULAR DISEASES   263

10.6.1    INCREASING INVESTMENT IN ADVANCED CARDIOVASCULAR THERAPIES TO AID MARKET GROWTH 263

TABLE 234         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES,  BY REGION, 2022–2029 (USD BILLION)  263

TABLE 235         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           264

TABLE 236         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              264

TABLE 237         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           265

TABLE 238         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           265

TABLE 239         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           266

TABLE 240         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           266

10.7       RESPIRATORY DISEASES            266

10.7.1    INCREASING POLLUTION LEVELS AND GROWING NUMBER OF COPD CASES TO FUEL MARKET GROWTH       266

TABLE 241         LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2022              267

TABLE 242         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES,  BY REGION, 2022–2029 (USD BILLION)           267

TABLE 243         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              268

TABLE 244         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)  268

TABLE 245         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              269

TABLE 246         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              269

TABLE 247         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              270

TABLE 248         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)              270

10.8       PAIN MANAGEMENT    270

10.8.1    INCREASING DEMAND FOR ADVANCED PAIN MEDICATIONS TO PROPEL MARKET GROWTH      270

TABLE 249         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT,  BY REGION, 2022–2029 (USD BILLION)             271

TABLE 250         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022–2029 (USD BILLION)              271

TABLE 251         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT,  BY COUNTRY, 2022–2029 (USD BILLION)     272

TABLE 252         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022–2029 (USD BILLION)              272

TABLE 253         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022–2029 (USD BILLION)              273

TABLE 254         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022–2029 (USD BILLION)              273

TABLE 255         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022–2029 (USD BILLION)              273

10.9       OTHER THERAPEUTIC APPLICATIONS 274

TABLE 256         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD BILLION)              274

TABLE 257         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 275

TABLE 258         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           275

TABLE 259         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 276

TABLE 260         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 276

TABLE 261         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 277

TABLE 262         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 277

11          ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER              278

11.1       INTRODUCTION            279

TABLE 263         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)           279

11.2       ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT)     279

TABLE 264         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)    279

TABLE 265         CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          280

11.3       PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY      280

11.3.1    INCREASING NUMBER OF COLLABORATIONS TO SUPPORT MARKET GROWTH          280

TABLE 266         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY REGION, 2022–2029 (USD BILLION) 281

TABLE 267         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,  2022–2029 (USD BILLION)  281

TABLE 268         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022–2029 (USD BILLION)      282

TABLE 269         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022–2029 (USD BILLION)     282

TABLE 270         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022–2029 (USD BILLION)     283

TABLE 271         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022–2029 (USD BILLION)     283

TABLE 272         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,  2022–2029 (USD BILLION)  283

11.4       CONTRACT RESEARCH ORGANIZATIONS          284

11.4.1    INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT MARKET GROWTH        284

TABLE 273         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD BILLION)           284

TABLE 274         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      284

TABLE 275         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           285

TABLE 276         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      285

TABLE 277         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      286

TABLE 278         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      286

TABLE 279         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      286

11.5       CONTRACT MANUFACTURING ORGANIZATIONS          287

11.5.1    INCREASED FOCUS ON BETTER QUALITY TO AID MARKET GROWTH              287

TABLE 280         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2022–2029 (USD BILLION)           287

TABLE 281         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           287

TABLE 282         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)      288

TABLE 283         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           288

TABLE 284         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           289

TABLE 285         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           289

TABLE 286         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD BILLION)           289

11.6       OTHER END USERS        290

TABLE 287         ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)         290

TABLE 288         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)              291

TABLE 289         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS,  BY COUNTRY, 2022–2029 (USD BILLION)        291

TABLE 290         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)              292

TABLE 291         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)              292

TABLE 292         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)              293

TABLE 293         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)              293

12          ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION 294

12.1       INTRODUCTION            295

TABLE 294         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION,  2022–2029 (USD BILLION)      295

12.2       ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT)     295

TABLE 295         ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT), 2022–2029 (USD BILLION)             296

TABLE 296         CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION,  2022–2029 (USD BILLION) 296

12.3       NORTH AMERICA          296

12.3.1    NORTH AMERICA: RECESSION IMPACT 297

FIGURE 34         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT     298

TABLE 297         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       298

TABLE 298         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  299

TABLE 299         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          299

TABLE 300         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)       299

TABLE 301         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)           300

TABLE 302         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)  300

TABLE 303         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           301

TABLE 304         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 301

TABLE 305         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        301

TABLE 306         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    302

TABLE 307         NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022–2029 (USD BILLION)          302

12.3.2    US         302

12.3.2.1 US to dominate North American active pharmaceutical ingredient market during study period         302

TABLE 308         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           303

TABLE 309         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  303

TABLE 310         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    304

TABLE 311         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        304

TABLE 312         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)             304

TABLE 313         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     305

TABLE 314         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       305

TABLE 315         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   305

TABLE 316         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             306

TABLE 317         US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)           306

12.3.3    CANADA            306

12.3.3.1 Growing pharmaceutical manufacturing industry to support market growth              306

TABLE 318         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     307

TABLE 319         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)          307

TABLE 320         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       308

TABLE 321         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 308

TABLE 322         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  309

TABLE 323         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              309

TABLE 324         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 310

TABLE 325         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           310

TABLE 326         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       311

TABLE 327         CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          311

12.4       EUROPE             311

12.4.1    EUROPE: RECESSION IMPACT   312

TABLE 328         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)          312

TABLE 329         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     313

TABLE 330         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             313

TABLE 331         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       313

TABLE 332         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 314

TABLE 333         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  314

TABLE 334         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              315

TABLE 335         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 315

TABLE 336         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           315

TABLE 337         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       316

TABLE 338         EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          316

12.4.2    GERMANY         316

12.4.2.1 High healthcare expenditure and advanced R&D facilities to drive market              316

TABLE 339         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     317

TABLE 340         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             317

TABLE 341         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       317

TABLE 342         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)           318

TABLE 343         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  318

TABLE 344         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              319

TABLE 345         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 319

TABLE 346         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           319

TABLE 347         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       320

TABLE 348         GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          320

12.4.3    UK         320

12.4.3.1 Rising government investments and growing focus on personalized treatment to drive market        320

TABLE 349         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           321

TABLE 350         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  321

TABLE 351         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    321

TABLE 352         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        322

TABLE 353         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)             322

TABLE 354         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     323

TABLE 355         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       323

TABLE 356         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   323

TABLE 357         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             324

TABLE 358         UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  324

12.4.4    FRANCE             325

12.4.4.1 Increased focus on domestic API manufacturing to boost market growth 325

TABLE 359         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     325

TABLE 360         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             325

TABLE 361         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       326

TABLE 362         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 326

TABLE 363         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  327

TABLE 364         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              327

TABLE 365         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 328

TABLE 366         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           328

TABLE 367         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       329

TABLE 368         FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          329

12.4.5    ITALY   330

12.4.5.1 Increasing investment in API production to fuel market growth 330

TABLE 369         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           330

TABLE 370         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  330

TABLE 371         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    331

TABLE 372         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        331

TABLE 373         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)           332

TABLE 374         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     332

TABLE 375         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       333

TABLE 376         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   333

TABLE 377         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             334

TABLE 378         ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  334

12.4.6    SPAIN   335

12.4.6.1 Increase in generic drug manufacturing capacity to propel market growth              335

TABLE 379         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           335

TABLE 380         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  335

TABLE 381         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    336

TABLE 382         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        336

TABLE 383         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)           337

TABLE 384         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     337

TABLE 385         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       338

TABLE 386         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   338

TABLE 387         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             339

TABLE 388         SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  339

12.4.7    HUNGARY         340

12.4.7.1 Increased focus on pharmaceutical manufacturing to drive market           340

TABLE 389         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     340

TABLE 390         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)          340

TABLE 391         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       341

TABLE 392         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 341

TABLE 393         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  342

TABLE 394         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              342

TABLE 395         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 343

TABLE 396         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           343

TABLE 397         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       344

TABLE 398         HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          344

12.4.8    REST OF EUROPE           344

TABLE 399         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  345

TABLE 400         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          345

TABLE 401         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)       345

TABLE 402         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)           346

TABLE 403         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)  346

TABLE 404         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           347

TABLE 405         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 347

TABLE 406         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        347

TABLE 407         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    348

TABLE 408         REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       348

12.5       ASIA PACIFIC    349

12.5.1    ASIA PACIFIC: RECESSION IMPACT        349

FIGURE 35         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT     350

TABLE 409         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       351

TABLE 410         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  351

TABLE 411         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)       351

TABLE 412         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)     352

TABLE 413         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         352

TABLE 414         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 352

TABLE 415         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           353

TABLE 416         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 353

TABLE 417         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        353

TABLE 418         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    354

TABLE 419         ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       354

12.5.2    JAPAN  354

12.5.2.1 Strong focus on drug innovation and improved R&D facilities to drive market              354

TABLE 420         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           355

TABLE 421         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  355

TABLE 422         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    356

TABLE 423         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        356

TABLE 424         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)           357

TABLE 425         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     357

TABLE 426         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       358

TABLE 427         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   358

TABLE 428         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             359

TABLE 429         JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  359

12.5.3    CHINA  359

12.5.3.1 High geriatric population and favorable government policies to support market growth   359

TABLE 430         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           360

TABLE 431         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  360

TABLE 432         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)          361

TABLE 433         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 361

TABLE 434         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  361

TABLE 435         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              362

TABLE 436         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       362

TABLE 437         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   362

TABLE 438         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             363

TABLE 439         CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  363

12.5.4    INDIA   363

12.5.4.1 Increased demand for biosimilars and favorable government healthcare policies to fuel market growth             363

TABLE 440         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           364

TABLE 441         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  364

TABLE 442         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)    365

TABLE 443         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)        365

TABLE 444         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)           366

TABLE 445         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)     366

TABLE 446         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       367

TABLE 447         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   367

TABLE 448         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             368

TABLE 449         INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  368

12.5.5    SOUTH KOREA 368

12.5.5.1 Increasing focus on quality manufacturing practices to drive market        368

TABLE 450         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  369

TABLE 451         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          369

TABLE 452         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)     370

TABLE 453         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         370

TABLE 454         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 371

TABLE 455         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           371

TABLE 456         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 372

TABLE 457         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        372

TABLE 458         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    373

TABLE 459         SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       373

12.5.6    AUSTRALIA       374

12.5.6.1 Increasing demand for innovative APIs to propel market growth 374

TABLE 460         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  374

TABLE 461         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          374

TABLE 462         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)     375

TABLE 463         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         375

TABLE 464         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 376

TABLE 465         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           376

TABLE 466         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)            377

TABLE 467         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        377

TABLE 468         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    378

TABLE 469         AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       378

12.5.7    REST OF ASIA PACIFIC  379

TABLE 470         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)      379

TABLE 471         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             380

TABLE 472         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)           380

TABLE 473         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)              380

TABLE 474         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)           381

TABLE 475         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION) 381

TABLE 476         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION)    382

TABLE 477         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           382

TABLE 478         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)           383

TABLE 479         REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022–2029 (USD BILLION)             383

12.6       LATIN AMERICA             384

12.6.1    LATIN AMERICA: RECESSION IMPACT   384

TABLE 480         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       384

TABLE 481         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  385

TABLE 482         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 (USD BILLION)        385

TABLE 483         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)       385

TABLE 484         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         386

TABLE 485         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 386

TABLE 486         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           387

TABLE 487         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 387

TABLE 488         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        387

TABLE 489         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    388

TABLE 490         LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       388

12.6.2    BRAZIL 389

12.6.2.1 Increased government investments in pharmaceutical R&D to drive market              389

TABLE 491         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           389

TABLE 492         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)     389

TABLE 493         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)          390

TABLE 494         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 390

TABLE 495         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  391

TABLE 496         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              391

TABLE 497         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       392

TABLE 498         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   392

TABLE 499         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             393

TABLE 500         BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  393

12.6.3    MEXICO             394

12.6.3.1 Large investments by foreign firms and favorable regulatory policies to augment market growth     394

TABLE 501         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)     394

TABLE 502         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             394

TABLE 503         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)       395

TABLE 504         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 395

TABLE 505         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  396

TABLE 506         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              396

TABLE 507         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION) 397

TABLE 508         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           397

TABLE 509         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)       398

TABLE 510         MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)          398

12.6.4    REST OF LATIN AMERICA          398

TABLE 511         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2029 (USD BILLION)        399

TABLE 512         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             399

TABLE 513         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)           399

TABLE 514         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)              400

TABLE 515         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)           400

TABLE 516         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION) 401

TABLE 517         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION)    401

TABLE 518         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           401

TABLE 519         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)           402

TABLE 520         REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022–2029 (USD BILLION)             402

12.7       MIDDLE EAST  402

12.7.1    MIDDLE EAST: RECESSION IMPACT       403

TABLE 521         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       403

TABLE 522         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  403

TABLE 523         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          404

TABLE 524         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS,  BY TYPE, 2022–2029 (USD BILLION)     404

TABLE 525         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         404

TABLE 526         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 405

TABLE 527         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           405

TABLE 528         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 406

TABLE 529         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        406

TABLE 530         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    407

TABLE 531         MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       407

12.7.2    ISRAEL 407

12.7.2.1 Growing financial support by government to drive market         407

TABLE 532         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           408

TABLE 533         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  408

TABLE 534         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)          408

TABLE 535         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 409

TABLE 536         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  409

TABLE 537         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              410

TABLE 538         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       410

TABLE 539         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   410

TABLE 540         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             411

TABLE 541         ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  411

12.7.3    GCC COUNTRIES           412

TABLE 542         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY,  2022–2029 (USD BILLION)       412

TABLE 543         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  412

TABLE 544         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)       413

TABLE 545         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)       413

TABLE 546         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)           413

TABLE 547         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)  414

TABLE 548         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           414

TABLE 549         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 415

TABLE 550         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        415

TABLE 551         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    416

TABLE 552         GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       416

12.7.3.1 United Arab Emirates        417

12.7.3.1.1            Growing demand for technologically advanced manufacturing processes to drive market    417

TABLE 553         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)      417

TABLE 554         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             417

TABLE 555         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)           418

TABLE 556         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)              418

TABLE 557         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)           419

TABLE 558         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION) 419

TABLE 559         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION)    420

TABLE 560         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           420

TABLE 561         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)           421

TABLE 562         UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)           421

12.7.3.2 Saudi Arabia        421

12.7.3.2.1            Rising healthcare expenditure and increasing number of research institutes to boost market growth     421

TABLE 563         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)  422

TABLE 564         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)          422

TABLE 565         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)       423

TABLE 566         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY TYPE, 2022–2029 (USD BILLION)         423

TABLE 567         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION) 424

TABLE 568         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)           424

TABLE 569         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION) 425

TABLE 570         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)        425

TABLE 571         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)    426

TABLE 572         SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)       426

12.7.3.3 Rest of GCC countries       426

TABLE 573         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2029 (USD BILLION)        427

TABLE 574         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 USD BILLION)             427

TABLE 575         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)           427

TABLE 576         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)              428

TABLE 577         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)           428

TABLE 578         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION) 429

TABLE 579         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION)    429

TABLE 580         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY POTENCY, 2022–2029 (USD BILLION)           429

TABLE 581         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)           430

TABLE 582         REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022–2029 (USD BILLION)             430

12.7.4    REST OF MIDDLE EAST 430

TABLE 583         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2029 (USD BILLION)        431

TABLE 584         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022–2029 (USD BILLION)            431

TABLE 585         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)           431

TABLE 586         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION)              432

TABLE 587         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022–2029 (USD BILLION)           432

TABLE 588         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION) 433

TABLE 589         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022–2029 (USD BILLION)    433

TABLE 590         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)           433

TABLE 591         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)           434

TABLE 592         REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022–2029 (USD BILLION)             434

12.8       AFRICA 435

12.8.1    GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET GROWTH        435

12.8.2    AFRICA: RECESSION IMPACT     435

TABLE 593         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE,  2022–2029 (USD BILLION)           435

TABLE 594         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS,  2022–2029 USD BILLION)  436

TABLE 595         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022–2029 (USD BILLION)          436

TABLE 596         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022–2029 (USD BILLION) 436

TABLE 597         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY PRODUCT, 2022–2029 (USD BILLION)  437

TABLE 598         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS,  BY EXPRESSION SYSTEM, 2022–2029 (USD BILLION)              437

TABLE 599         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG,  2022–2029 (USD BILLION)       438

TABLE 600         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY,  2022–2029 (USD BILLION)   438

TABLE 601         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022–2029 (USD BILLION)             439

TABLE 602         AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER,  2022–2029 (USD BILLION)  439

13          COMPETITIVE LANDSCAPE       440

13.1       INTRODUCTION            440

13.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          440

TABLE 603         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: STRATEGIES ADOPTED 440

13.3       REVENUE ANALYSIS      441

FIGURE 36         REVENUE ANALYSIS OF KEY PLAYERS, 2019–2023 (USD MILLION)          442

13.4       MARKET SHARE ANALYSIS         442

FIGURE 37         MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)        443

TABLE 604         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DEGREE OF COMPETITION         443

13.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   445

13.5.1    STARS  445

13.5.2    EMERGING LEADERS    445

13.5.3    PERVASIVE PLAYERS     445

13.5.4    PARTICIPANTS 445

FIGURE 38         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023      446

13.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      447

13.5.5.1 Overall footprint  447

FIGURE 39         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: OVERALL FOOTPRINT      447

13.5.5.2 Type footprint     448

TABLE 605         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TYPE FOOTPRINT      448

13.5.5.3 Therapeutic application footprint    449

TABLE 606         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: THERAPEUTIC APPLICATION FOOTPRINT        449

13.5.5.4 Type of drug footprint       450

TABLE 607         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TYPE OF DRUG FOOTPRINT        450

13.5.5.5 Regional footprint              451

TABLE 608         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONAL FOOTPRINT      451

13.6       COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023         452

13.6.1    PROGRESSIVE COMPANIES       452

13.6.2    RESPONSIVE COMPANIES          452

13.6.3    DYNAMIC COMPANIES 452

13.6.4    STARTING BLOCKS       452

FIGURE 40         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023             453

13.6.5    COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023           453

TABLE 609         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES, 2023            453

TABLE 610         ACTIVE PHARMACEUTICAL INGREDIENTS: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES, BY TYPE AND REGION       454

13.7       VALUATION AND FINANCIAL METRICS 455

FIGURE 41         EV/EBITDA OF KEY ACTIVE PHARMACEUTICAL INGREDIENT VENDORS          455

FIGURE 42         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF  KEY ACTIVE PHARMACEUTICAL INGREDIENT VENDORS              456

13.8       BRAND/PRODUCT COMPARISON          456

FIGURE 43         BRAND/PRODUCT COMPARISON, BY ACTIVE PHARMACEUTICAL INGREDIENT  TYPE            456

13.9       COMPETITIVE SCENARIO          457

13.9.1    DEALS  457

TABLE 611         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DEALS, JANUARY 2021–JANUARY 2024   457

13.9.2    EXPANSIONS    458

TABLE 612         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: EXPANSIONS,  JANUARY 2021–JANUARY 2024    459

13.9.3    OTHER DEVELOPMENTS           460

TABLE 613         ACTIVE PHARMACEUTICAL INGREDIENT MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2024             460

14          COMPANY PROFILES    461

14.1       KEY PLAYERS   461

(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats)*

14.1.1    PFIZER INC.       461

TABLE 614         PFIZER INC.: COMPANY OVERVIEW       461

FIGURE 44         PFIZER INC.: COMPANY SNAPSHOT (2023)         462

TABLE 615         PFIZER INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              462

TABLE 616         PFIZER INC.: EXPANSIONS         463

14.1.2    TEVA PHARMACEUTICAL INDUSTRIES LTD.     465

TABLE 617         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW        465

FIGURE 45         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)          465

TABLE 618         TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   466

TABLE 619         TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS      473

14.1.3    GSK PLC            475

TABLE 620         GSK PLC: COMPANY OVERVIEW             475

FIGURE 46         GSK PLC: COMPANY SNAPSHOT (2023) 476

TABLE 621         GSK PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 476

TABLE 622         GSK PLC: EXPANSIONS 477

14.1.4    SANOFI 479

TABLE 623         SANOFI: COMPANY OVERVIEW 479

FIGURE 47         SANOFI: COMPANY SNAPSHOT (2023)   480

TABLE 624         SANOFI: PRODUCTS/SERVICES/SOLUTIONS OFFERED  480

14.1.5    VIATRIS INC.     482

TABLE 625         VIATRIS INC.: COMPANY OVERVIEW     482

FIGURE 48         VIATRIS INC.: COMPANY SNAPSHOT (2023)       483

TABLE 626         VIATRIS INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              483

TABLE 627         VIATRIS INC.: DEALS     487

TABLE 628         VIATRIS INC.: EXPANSIONS        487

14.1.6    DIVI’S LABORATORIES LIMITED             488

TABLE 629         DIVI’S LABORATORIES LIMITED: COMPANY OVERVIEW 488

FIGURE 49         DIVI’S LABORATORIES LIMITED: COMPANY SNAPSHOT (2023)              488

TABLE 630         DIVI’S LABORATORIES LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED   489

TABLE 631         DIVI’S LABORATORIES LIMITED: DEALS             490

14.1.7    SANDOZ GROUP AG      491

TABLE 632         SANDOZ GROUP AG: COMPANY OVERVIEW      491

FIGURE 50         SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)        492

TABLE 633         SANDOZ GROUP AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED          492

TABLE 634         SANDOZ GROUP AG: EXPANSIONS         493

14.1.8    BOEHRINGER INGELHEIM INTERNATIONAL GMBH       494

TABLE 635         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW        494

FIGURE 51         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)          495

TABLE 636         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED   495

TABLE 637         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS              496

TABLE 638         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS    497

14.1.9    SK INC. 498

TABLE 639         SK INC.: COMPANY OVERVIEW 498

FIGURE 52         SK INC.: COMPANY SNAPSHOT (2023)   499

TABLE 640         SK INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED  499

TABLE 641         SK INC.: EXPANSIONS    500

14.1.10  ELI LILLY AND COMPANY          501

TABLE 642         ELI LILLY AND COMPANY: COMPANY OVERVIEW          501

FIGURE 53         ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)              502

TABLE 643         ELI LILLY AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED          502

TABLE 644         ELI LILLY AND COMPANY: DEALS          503

TABLE 645         ELI LILLY AND COMPANY: EXPANSIONS             504

TABLE 646         ELI LILLY AND COMPANY: OTHER DEVELOPMENTS     504

14.1.11  MERCK KGAA   505

TABLE 647         MERCK KGAA: COMPANY OVERVIEW    505

FIGURE 54         MERCK KGAA: COMPANY SNAPSHOT (2023)      506

TABLE 648         MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED              506

TABLE 649         MERCK KGAA: EXPANSIONS      507

14.1.12  ABBVIE INC.      508

TABLE 650         ABBVIE INC.: COMPANY OVERVIEW      508

FIGURE 55         ABBVIE INC.: COMPANY SNAPSHOT (2023)        509

TABLE 651         ABBVIE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              509

TABLE 652         ABBVIE INC.: DEALS      510

TABLE 653         ABBVIE INC.: EXPANSIONS         510

14.1.13  F. HOFFMANN-LA ROCHE LTD. 511

FIGURE 56         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)              512

TABLE 654         F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   512

14.1.14  ASTRAZENECA 513

TABLE 655         ASTRAZENECA: COMPANY OVERVIEW  513

FIGURE 57         ASTRAZENECA: COMPANY SNAPSHOT (2023)    514

TABLE 656         ASTRAZENECA: PRODUCTS/SERVICES/SOLUTIONS OFFERED              514

TABLE 657         ASTRAZENECA: PRODUCT LAUNCHES  515

TABLE 658         ASTRAZENECA: EXPANSIONS    515

14.1.15  DR. REDDY’S LABORATORIES LTD.        516

TABLE 659         DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW              516

FIGURE 58         DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)   517

TABLE 660         DR. REDDY’S LABORATORIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   517

TABLE 661         DR. REDDY’S LABORATORIES LTD.: EXPANSIONS           519

TABLE 662         DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS              519

14.1.16  SUN PHARMACEUTICAL INDUSTRIES LTD.        520

TABLE 663         SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW        520

FIGURE 59         SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)          521

TABLE 664         SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   521

TABLE 665         SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS        523

14.1.17  CIPLA   524

TABLE 666         CIPLA: COMPANY OVERVIEW   524

FIGURE 60         CIPLA: COMPANY SNAPSHOT (2023)     525

TABLE 667         CIPLA: PRODUCTS/SERVICES/SOLUTIONS OFFERED    525

TABLE 668         CIPLA: DEALS   527

14.1.18  AUROBINDO PHARMA  528

TABLE 669         AUROBINDO PHARMA: COMPANY OVERVIEW  528

FIGURE 61         AUROBINDO PHARMA: COMPANY SNAPSHOT (2023)    529

TABLE 670         AUROBINDO PHARMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED          529

TABLE 671         AUROBINDO PHARMA: DEALS  530

14.1.19  EVONIK INDUSTRIES AG            531

TABLE 672         EVONIK INDUSTRIES AG: COMPANY OVERVIEW             531

FIGURE 62         EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023) 532

TABLE 673         EVONIK INDUSTRIES AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED          532

TABLE 674         EVONIK INDUSTRIES AG: DEALS            533

TABLE 675         EVONIK INDUSTRIES AG: EXPANSIONS 534

14.1.20  HIKMA PHARMACEUTICALS PLC           535

TABLE 676         HIKMA PHARMACEUTICALS PLC: COMPANY OVERVIEW              535

FIGURE 63         HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)              536

TABLE 677         HIKMA PHARMACEUTICALS PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED   536

TABLE 678         HIKMA PHARMACEUTICALS PLC: DEALS            537

14.1.21  BASF SE              538

TABLE 679         BASF SE: COMPANY OVERVIEW 538

FIGURE 64         BASF SE: COMPANY SNAPSHOT (2023)  539

TABLE 680         BASF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 539

14.1.22  ALEMBIC PHARMACEUTICALS LIMITED             541

TABLE 681         ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW        541

FIGURE 65         ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)          542

TABLE 682         ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED   542

14.2       OTHER PLAYERS           544

14.2.1    ABURAIHAN PHARMACEUTICAL COMPANY      544

TABLE 683         ABURAIHAN PHARMACEUTICAL COMPANY: COMPANY OVERVIEW        544

14.2.2    CURIA GLOBAL, INC.     545

TABLE 684         CURIA GLOBAL, INC.: COMPANY OVERVIEW     545

14.2.3    CAMBREX CORPORATION         546

TABLE 685         CAMBREX CORPORATION: COMPANY OVERVIEW          546

14.2.4    API PHARMA TECH       547

TABLE 686         API PHARMA TECH: COMPANY OVERVIEW        547

14.2.5    SREEPATHI PHARMACEUTICALS LIMITED         548

TABLE 687         SREEPATHI PHARMACEUTICALS LIMITED: COMPANY OVERVIEW        548

14.2.6    SHILPA MEDICARE LIMITED     549

TABLE 688         SHILPA MEDICARE LIMITED: COMPANY OVERVIEW      549

14.2.7    NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.              550

TABLE 689         NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW      550

14.2.8    HOVIONE          551

TABLE 690         HOVIONE: COMPANY OVERVIEW           551

14.2.9    CHEMCON GMBH          552

TABLE 691         CHEMCON GMBH: COMPANY OVERVIEW          552

14.2.10  PHARCO            553

TABLE 692         PHARCO: COMPANY OVERVIEW             553

*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

15          APPENDIX         554

15.1       DISCUSSION GUIDE      554

15.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             559

15.3       CUSTOMIZATION OPTIONS      561

15.4       RELATED REPORTS       561

15.5       AUTHOR DETAILS         562